Organisation paid for research Program year 2025 Source: CMS Open Payments

Community Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$6,328,008

112 payments

Through program year 2025, Community Clinical Research is reported as receiving $6,328,008 in research payments, across 112 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $393,622 16
2024 Research $85,054 9
2023 Research $23,309 4
2022 Research $330,841 18
2021 Research $1,740,152 31
2020 Research $2,535,237 8
2019 Research $1,219,793 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $3,926,683 7 payments
  2. Teva Pharmaceuticals USA, Inc. $870,601 16 payments
  3. Hoffmann-La Roche Limited $627,621 12 payments
  4. E.R. Squibb & Sons, L.L.C. $367,671 11 payments
  5. Allergan Inc. $300,747 22 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $157,885 15 payments
  7. GlaxoSmithKline, LLC. $47,048 5 payments
  8. Moderna TX, Inc. $20,085 2 payments
  9. Boehringer Ingelheim RCV GmbH & Co KG $7,266 19 payments
  10. AbbVie, Inc. $2,402 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder $2,264,547 2 payments
  2. A Phase-1, Open-label, Randomized, Single Ascending Dose Trial to determine the PK, Safety and Tolerability of Brexpiprazole Long-Acting Injectable in Adult Subjects with Schizophrenia $929,159 3 payments
  3. Tv44749-Sad-10154 $870,601 16 payments
  4. An Open-Label, Single- and Multiple-Dose, Pharmacokinetic, Safety, and Tolerability Trial of Aripiprazole Long-Acting Injectable Administered in the Deltoid Or Gluteal Muscle in Adult Subjects With Schizophrenia Or Bipolar I Disorder $732,977 2 payments
  5. Acute Schizophrenia Study $627,621 12 payments
  6. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $184,876 14 payments
  7. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $124,066 1 payment
  8. A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $103,744 1 payment
  9. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $99,267 5 payments
  10. Connex 1 $63,083 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record